Guest guest Posted March 18, 1999 Report Share Posted March 18, 1999 Some information about Ampligen which you may not have been told about is on the FDA's website at www.fda.gov . Just click on " Biologics " and then do a search for " Ampligen. " Two of the 8 documents you'll get relate to Ampligen and CFS: (1) the FDA's rejection of HEM's IND application dated October 4, 1991 based on potentially deadly side effects which happened to some patients in the trial and the generally poor conduct of the study; and (2) the warning letter the FDA sent to Hemispherx on October 15, 1998 ordering them to stop their illegal promotion of Ampligen. Public record documents from the lawsuit filed against HEM (the old name for Hemispherx) in 1992 by former Ampligen patients include a 1991 letter from Kessler, then Commissioner of the FDA, which states, " Severe drug reactions were not reported to the FDA. For example, [patient identification deleted] received Ampligen and two hours post-infusion experienced severe abdominal pain and tachycardia requiring hospitalization. Hepatic [liver] enzymes were 'severely elevated' and the condition was diagnosed as 'acute hepatic toxicity' and 'acute drug reaction secondary to Ampligen administration' ... Other 'severe post-infusion reactions' were noted on [patient identification deleted] ... this patient experienced severe flu-like symptoms, severe swelling, redness, and itching of hands and extremities. Four additional adverse reaction reports were found. " The letter also states that " Twelve patients out of 45 experienced deterioration of Karnofsky Performance scores and 16 patients out of 45 experienced deterioration of Activity of Daily Living (ADL) scores during the course of [Ampligen] treatment. " Gosh, I can't remember Hemispherx ever saying that a third of the patients who took Ampligen got sicker, can you? Another letter from the same court record is from Dr. Gerald V. Quinnan, Jr., who then was Acting Director of the FDA's Center for Biologics Evaluation and Research. In the letter he warns Hemispherx CEO Dr. not to make inaccurate public statements about Ampligen: " A balanced presentation would require a clear statement regarding the risks of Ampligen, including a statement that a number of serious and potentially life-threatening reactions were observed. " An advocacy project I'm getting involved in is to change federal law so that patients who take experimental drugs are legally entitled to ALL information about the drugs, and to give the FDA the power to enforce that law. Right now all information about any experimental drug is the sole property of the pharmaceutical company. The FDA is legally prohibited from telling patients what it knows about any drug that hasn't been approved yet, even if the patients' lives could be in danger because they haven't been told the truth. As for CFS Radio: On October 25, 1998 (ten days after the FDA ordered them to stop their illegal press releases and Internet promotions), Hemispherx became the sole sponsor of the CFS Radio program. You may have noticed that nearly all the broadcasts since then promote Ampligen in some way. I have audiotapes of all the broadcasts, and the broadcasts themselves include the announcement that Hemispherx is paying for them. However, Carolyn Viviani deletes those announcements from the transcripts she publishes on the Internet, so that readers do not know that Hemispherx has paid for everything they are reading. I don't know why Carolyn withholds this information, or who may have told her to do so. , is " Mitch " Mitch Abrams? If so, I suggest you check out his financial ties to Hemispherx Biopharma. And please, please inform the FDA immediately about what he has said to you. If you email me at cfsmail@..., I'll send you the name and phone number of the FDA person in charge of this. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.